Hexagon Nutrition IPO Review 2026: Price Band, Nutrition Business, Financials and Bullrun View
Hexagon Nutrition IPO Review 2026: Price Band, Nutrition Business, Financials and Bullrun View
A detailed Bullrun review of Hexagon Nutrition IPO covering price band, OFS structure, nutrition business, financials, valuation, risks and investor suitability.
Hexagon Nutrition IPO: A Nutrition Platform Coming Through OFS
Hexagon Nutrition is a research-oriented nutrition company operating across micronutrient premixes, clinical nutrition, therapeutic foods and nutrition solutions. Public summaries describe the company as a pioneer in micronutrient premix formulations and an integrated nutrition platform.
The category is structurally attractive because food fortification, wellness, clinical nutrition and malnutrition solutions have long-term relevance. But investors must remember that this IPO is structured as an Offer for Sale, so the company does not receive fresh growth capital.
Bullrun lens: Hexagon Nutrition has a differentiated category and improving profitability, but the OFS-only structure makes valuation and selling shareholder intent important.
IPO Terms
| IPO Detail | Information |
|---|---|
| Status | Upcoming Mainboard IPO |
| Open | 5 June 2026 |
| Close | 9 June 2026 |
| Anchor Bidding | 4 June 2026 |
| Allotment | 10 June 2026 |
| Listing | 12 June 2026 |
| Price Band | ₹42 to ₹45 |
| Lot Size | 333 shares |
| Issue Size | About ₹138.87 crore |
| Issue Structure | 100% Offer for Sale |
| Exchange | BSE and NSE |
| Registrar | KFin Technologies Ltd. |
| Lead Managers | Cumulative Capital and Catalyst Capital Partners in public summaries |
Business Model: Premixes, Clinical Nutrition and Therapeutic Foods
Hexagon operates across B2B premix formulations, branded wellness and clinical nutrition, and nutrition solutions such as ready-to-use foods and micronutrient powders. This gives it both institutional and consumer-facing optionality.
The business needs R&D, quality consistency, regulatory comfort and customer trust. Nutrition is a promising market, but product credibility matters more than marketing language.
Financial Performance: Profit Growth Is Visible
Public summaries show FY25 total income around ₹331.29 crore, EBITDA around ₹40.07 crore and PAT around ₹24.38 crore. FY24 PAT was around ₹12.21 crore and FY23 PAT around ₹5.82 crore, indicating improving profitability.
The EBITDA improvement suggests operating leverage. Investors should check whether margin gains come from product mix, scale, exports or one-time effects.
Valuation and OFS Lens
At the upper band of ₹45, public tracker analysis indicates a market-cap framework around ₹553 crore and P/E around the mid-teens on annualised data. This should be tested against growth durability and return ratios.
The OFS-only structure is the main caveat. Existing shareholders are selling shares, and the company will not receive fresh funds. That does not make the issue unattractive, but it changes the investment thesis.
| Analysis Point | Bullrun Interpretation |
|---|---|
| Positive signal | Nutrition category has long-term demand |
| Main concern | 100% OFS means no fresh proceeds |
| Margin check | Study EBITDA and PAT margin trend |
| Valuation check | Compare P/E with branded nutrition and FMCG peers |
Offer for Sale Structure
Since the issue is an OFS, proceeds go to selling shareholders.
- Provide liquidity to existing shareholders.
- Enable public market listing and price discovery.
- No fresh capital is raised for company expansion.
- Investors should evaluate post-listing supply and selling shareholder intent.
Strengths Investors Can Consider
- Differentiated nutrition and premix business.
- FY25 PAT and EBITDA improved from FY24.
- Mainboard listing may provide better liquidity.
- Exposure to food fortification, wellness and clinical nutrition.
- Valuation appears measurable because price band is announced.
Risks and Red Flags
- 100% OFS does not fund company growth.
- Nutrition products require quality and regulatory trust.
- Margins can vary across product segments.
- Growth depends on R&D and customer relationships.
- Selling shareholder supply should be understood.
Bullrun Investor View
Hexagon Nutrition IPO is a quality watchlist candidate because the category is differentiated and profitability is improving. The main caution is the OFS-only structure. Investors should apply only if valuation is comfortable after checking the RHP.
Investor Questions
Is Hexagon Nutrition IPO good for listing gains?
Listing gains depend on subscription strength, GMP movement, allotment demand and the broader market mood. The GMP should be treated as a short-term sentiment signal, not as a substitute for business analysis.
What should investors check before applying?
Read the RHP, financial statements, objects of the issue, borrowings, working capital, promoter holding, peer valuation and subscription data. For SME IPOs, post-listing liquidity is as important as allotment chance.
Is this IPO suitable for conservative investors?
Conservative investors should avoid applying only because an IPO is live or because GMP is positive. They should apply only where business quality, valuation and liquidity risk are all acceptable.